Hikma Pharmaceuticals Plc (LON:HIK) has received an average rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is GBX 1,781.67 ($23.28).
Several research analysts recently commented on the stock. Peel Hunt reiterated a “hold” rating and set a GBX 2,050 ($26.79) price objective (up previously from GBX 1,870 ($24.43)) on shares of Hikma Pharmaceuticals in a research note on Friday, August 9th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 1,700 ($22.21) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Finally, Barclays boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 ($23.52) to GBX 1,900 ($24.83) and gave the stock an “equal weight” rating in a research note on Tuesday.
Shares of LON HIK traded down GBX 7 ($0.09) during trading hours on Friday, hitting GBX 2,033 ($26.56). 389,308 shares of the stock were exchanged, compared to its average volume of 822,138. The company has a quick ratio of 0.78, a current ratio of 1.28 and a debt-to-equity ratio of 37.69. The company has a market cap of $4.93 billion and a PE ratio of 13.66. The firm has a fifty day moving average price of GBX 1,867.74 and a 200-day moving average price of GBX 1,748.87. Hikma Pharmaceuticals has a 12 month low of GBX 1,491.50 ($19.49) and a 12 month high of GBX 2,089 ($27.30).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Featured Article: What is the Quick Ratio?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.